NATCO Pharma Ltd. moves to reshape its capital structure

The specific split of the stated Rs 1,275 crore rights-issue proceeds could not be confirmed.

• Debt reduction: N/D — not separately disclosed.
• General corporate purposes and/or working capital: N/D — not separately disclosed.
• Reconciliation: The Letter of Offer does not provide a verifiable rupee allocation between these uses, so the portion assigned to debt reduction versus general corporate purposes or working capital cannot be determined.

The allotment of 1.7 crore shares increases the company’s paid-up equity share capital by Rs 3.40 Crores, assuming the Rs 2 face value per share. The implied equity share capital rises from Rs 35.80 Crores to Rs 39.20 Crores. The pre-issue capital is reported at Rs 35.80 Crores ^[1], and the face value is Rs 2 per share ^[2].

Promoter ownership changes only marginally:

• Pre-issue: 49.42% in Q1 FY27
• Post-issue: 49.39% in Q2 FY27
• Change: down 0.03 percentage points

Thus, the issuance results in a Rs 3.40 Crores increase in paid-up share capital and negligible promoter dilution of 0.03 pp, indicating that the promoter percentage remained broadly stable after the allotment.

This calculation addresses paid-up equity share capital. Any increase in total shareholders’ equity would also depend on the issue price, securities premium and issue expenses, which are not established here.

Rs 750 was priced well above Natco Pharma’s latest audited book value, while the use of proceeds does include deleveraging—but not as a peer-relative balance-sheet catch-up strategy.

Issue price versus audited book value

Natco’s latest audited year-end is 31 March 2026 ^[3]. Its FY26 book value per share was Rs 257.57 ^[4], compared with the rights issue price of Rs 750 per share ^[5].

• Issue price / book value: 2.91x, derived as Rs 750 / Rs 257.57.
• Premium to book value: Rs 492.43 per share, or approximately 191.18% above book value.
• The price therefore represents a substantial premium to accounting book value; it is not a rights issue priced close to net asset value.

Does the pricing reflect a deleveraging strategy?

The use of proceeds does support absolute deleveraging. Of the stated net proceeds of Rs 1,259 Crores, Rs 810.50 Crores is earmarked for prepayment or repayment of borrowings, equivalent to approximately 64.38% of net proceeds; the balance is allocated to R&D and general corporate purposes ^[5].

However, a management statement specifically linking the Rs 750 pricing to peer-relative leverage reduction could not be confirmed. The available issue commentary identifies the price as approximately 11% below the prevailing market price when the terms were announced ^[6], but that is a market-price comparison, not a disclosed management rationale for the price.

Leverage relative to the named pharmaceutical comparators

FY26 year-end leverage was as follows. The comparison is directional because AstraZeneca Pharma India is shown on a standalone basis, while the other companies are consolidated.

Analyst read: Natco was already less levered than the four other consolidated comparators on both gross debt/equity and net debt/EBITDA; AstraZeneca is the exception, with zero reported debt and a net-cash position. The rights issue therefore appears designed to reduce Natco’s absolute borrowings while funding R&D and corporate requirements, rather than to bring an unusually levered balance sheet in line with domestic peers. The Rs 750 price itself is better understood as a capital-raising and shareholder-participation price than as evidence of a book-value-based deleveraging rationale.

_Scope note: this comparison also included AstraZenca Pharma India Ltd. (ASTRAZEN), which the answer above does not cover. Ask about any of them for a full side-by-side._